Insight Molecular Diagnostics Inc.
IMDX- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- SEC CIK
- 0001642380
No open-market purchases or sales by Insight Molecular Diagnostics Inc. insiders were filed in the last 90 days; 40 institutions reported holding it in 13F filings for Q2 2026, worth $108.9M in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 8, 2026, 1:48 PM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2025: $50.2M (1238.5% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024! | FY2023! | FY2022! | FY2021! |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 26, 2026 | Mar 24, 2025 | Apr 12, 2024 | Mar 31, 2023 | Mar 10, 2022 |
| Revenue | $4.05M | $1.88M | $1.50M | $958.0K | $7.73M |
| Cost of revenue | $1.75M | $1.05M | $1.00M | $880.0K | $4.18M |
| Gross profit | $2.30M | $740.0K | $413.0K | -$18.0K | $188.0K |
| Operating expenses | $53.4M | $61.8M | $25.5M | $18.0M | $74.4M |
| Research and development | $15.9M | $9.84M | $9.29M | $7.30M | $13.6M |
| Selling, general and administrative | $10.6M | $10.2M | $11.2M | $21.9M | $22.3M |
| Operating income | -$51.1M | -$61.0M | -$25.1M | -$18.0M | -$74.2M |
| Income tax | $0 | $0 | – | – | -$9.26M |
| Net income | -$50.2M | -$60.7M | -$27.8M | -$72.9M | -$64.1M |
| EPS, basic | $-1.65 | $-4.66 | $-3.75 | $-0.66 | – |
| EPS, diluted | $-1.65 | $-4.66 | $-3.75 | – | – |
| Weighted shares, basic | 30.5M | 13.1M | 7.65M | 110.8K | – |
| Weighted shares, diluted | 30.5M | 13.1M | 7.65M | – | – |
| Margins and growth | |||||
| Gross margin | 56.7% | 39.3% | 27.5% | -1.9% | 2.4% |
| Operating margin | -1260.8% | -3245.1% | -1672.4% | -1878.6% | -960.4% |
| Net margin | -1238.5% | -3225.0% | -1848.4% | -7609.8% | -829.5% |
| Revenue growth, year over year | +115.6% | +25.1% | +56.9% | −87.6% | +535.4% |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023! | FY2022! | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 26, 2026 | Mar 24, 2025 | Apr 12, 2024 | Mar 31, 2023 | Mar 10, 2022 |
| Cash and equivalents | $11.6M | $8.64M | $9.43M | $20.0M | $35.6M |
| Accounts receivable | $1.13M | $1.61M | $484.0K | $2.01M | $1.44M |
| Inventory | $446.0K | $410.0K | – | – | – |
| Total current assets | $15.3M | $11.8M | $10.7M | $25.5M | $39.1M |
| Property, plant and equipment | $9.25M | $5.98M | $4.71M | $8.71M | $7.29M |
| Goodwill | – | – | – | – | $18.7M |
| Intangible assets | $0 | $14.6M | $56.6M | $61.6M | $91.2M |
| Total assets | $25.8M | $35.1M | $74.9M | $100.1M | $159.6M |
| Accounts payable | $2.54M | $2.28M | $953.0K | $1.25M | $2.45M |
| Total current liabilities | $12.1M | $7.28M | $7.19M | $12.1M | $14.1M |
| Total liabilities | $57.2M | $47.4M | $49.3M | $60.5M | $94.3M |
| Shareholders' equity | -$31.5M | -$12.3M | $20.5M | $34.3M | $65.2M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 26, 2026 | Mar 24, 2025 | Apr 12, 2024 | Mar 31, 2023 | Mar 10, 2022 |
| Operating cash flow | -$22.2M | -$20.7M | -$23.3M | -$45.6M | -$35.9M |
| Capital expenditures | $3.19M | $516.0K | $281.0K | $4.34M | $2.25M |
| Free cash flow | -$25.4M | -$21.2M | -$23.6M | -$49.9M | -$38.2M |
| Depreciation and amortization | $2.20M | $1.56M | $1.59M | $1.50M | $844.0K |
| Stock-based compensation | $2.22M | $1.75M | $2.76M | $10.0M | $6.84M |
| Investing cash flow | -$3.19M | -$512.0K | -$932.0K | -$4.34M | -$14.0M |
| Financing cash flow | $28.1M | $20.4M | $12.2M | $35.8M | $78.4M |
| Net change in cash | $2.58M | -$796.0K | -$12.1M | -$14.1M | $28.5M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 54.7% | 93.2% | 183.6% | 1048.2% | 88.5% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Aug 3, 2026 | 32.7M | +14.3% | SEC |
| May 4, 2026 | 32.3M | +12.9% | SEC |
| Mar 19, 2026 | 32.2M | +12.5% | SEC |
| Nov 3, 2025 | 28.7M | +70.3% | SEC |
| Aug 4, 2025 | 28.6M | +114.1% | SEC |
| May 5, 2025 | 28.6M | +114.0% | SEC |
| Mar 17, 2025 | 28.6M | +245.7% | SEC |
| Nov 5, 2024 | 16.8M | +103.8% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
- A column marked ! failed an accounting identity (gross profit = revenue − cost of revenue, or assets = liabilities + equity, within 1%). Its numbers are shown as filed.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits. Stock splits since Dec 31, 2020, from 13F share counts: 1-for-20 in Q3 2023.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.